ACAD
Price
$22.20
Change
-$0.30 (-1.33%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
3.72B
33 days until earnings call
PGEN
Price
$1.44
Change
-$0.06 (-4.00%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
422.11M
45 days until earnings call
Interact to see
Advertisement

ACAD vs PGEN

Header iconACAD vs PGEN Comparison
Open Charts ACAD vs PGENBanner chart's image
ACADIA Pharmaceuticals
Price$22.20
Change-$0.30 (-1.33%)
Volume$22.88K
Capitalization3.72B
Precigen
Price$1.44
Change-$0.06 (-4.00%)
Volume$18.18K
Capitalization422.11M
ACAD vs PGEN Comparison Chart in %
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACAD vs. PGEN commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ACAD: $22.21 vs. PGEN: $1.43)
Brand notoriety: ACAD and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 80% vs. PGEN: 92%
Market capitalization -- ACAD: $3.72B vs. PGEN: $422.11M
ACAD [@Biotechnology] is valued at $3.72B. PGEN’s [@Biotechnology] market capitalization is $422.11M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The average market capitalization across the [@Biotechnology] industry is $2.35B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ACAD is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 5 bearish.
  • PGEN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than PGEN.

Price Growth

ACAD (@Biotechnology) experienced а -2.59% price change this week, while PGEN (@Biotechnology) price change was -4.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

Reported Earning Dates

ACAD is expected to report earnings on Jul 30, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($3.72B) has a higher market cap than PGEN($422M). PGEN YTD gains are higher at: 27.679 vs. ACAD (21.035). ACAD has higher annual earnings (EBITDA): 102M vs. PGEN (-154.85M). ACAD has more cash in the bank: 682M vs. PGEN (80.2M). PGEN has less debt than ACAD: PGEN (5.42M) vs ACAD (56M). ACAD has higher revenues than PGEN: ACAD (996M) vs PGEN (4.2M).
ACADPGENACAD / PGEN
Capitalization3.72B422M881%
EBITDA102M-154.85M-66%
Gain YTD21.03527.67976%
P/E Ratio16.21N/A-
Revenue996M4.2M23,709%
Total Cash682M80.2M850%
Total Debt56M5.42M1,034%
FUNDAMENTALS RATINGS
ACAD vs PGEN: Fundamental Ratings
ACAD
PGEN
OUTLOOK RATING
1..100
6421
VALUATION
overvalued / fair valued / undervalued
1..100
64
Fair valued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
26100
PRICE GROWTH RATING
1..100
4140
P/E GROWTH RATING
1..100
99100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (64) in the Biotechnology industry is in the same range as PGEN (70) in the null industry. This means that ACAD’s stock grew similarly to PGEN’s over the last 12 months.

ACAD's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that ACAD’s stock grew similarly to PGEN’s over the last 12 months.

ACAD's SMR Rating (26) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that ACAD’s stock grew significantly faster than PGEN’s over the last 12 months.

PGEN's Price Growth Rating (40) in the null industry is in the same range as ACAD (41) in the Biotechnology industry. This means that PGEN’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's P/E Growth Rating (99) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that ACAD’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADPGEN
RSI
ODDS (%)
Bearish Trend 2 days ago
73%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 9 days ago
73%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
72%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
88%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MADE26.380.36
+1.39%
iShares U.S. Manufacturing ETF
IMCV75.430.65
+0.87%
iShares Morningstar Mid-Cap Value ETF
DEM45.250.38
+0.85%
WisdomTree Emerging Markets High Div ETF
EMXF42.840.24
+0.56%
iShares ESG Advanced MSCI EM ETF
BBLU13.590.06
+0.44%
EA Bridgeway Blue Chip ETF

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-4.67%
ARCT - PGEN
47%
Loosely correlated
+3.30%
PRME - PGEN
45%
Loosely correlated
+9.50%
CRSP - PGEN
45%
Loosely correlated
-0.17%
XENE - PGEN
44%
Loosely correlated
+1.39%
ALEC - PGEN
44%
Loosely correlated
+0.67%
More